Taken together, administration of anti-ANGPTL3/IL22 fusion protein may be a more desirable therapeutic strategy than co-administration of anti-ANGPTL3 and IL-22 in the treatment of DN. This evidence concerns the gene ANGPTL3 and liver dysplastic nodule.